At Medicines Discovery Catapult (MDC), we support drug discovery innovators by providing world-leading scientific and drug discovery expertise, state-of-the-art laboratory facilities and infrastructure, with advanced technologies and analytics. 

We are driving the adoption of new scientific tools and techniques like Mass Spectrometry Imaging, Digital Spatial Profiling, Advanced Microscopy, Clinical Imaging, Radiochemistry, Positron Emission Tomography (PET), Bioluminescence / NIR Imaging (IVIS) and Super Resolution Microscopy. We are leveraging our key capabilities across translational imaging, biomarkers, cellular sciences, informatics, virtual R&D and syndicates.

MDC will enable medicines discovery to be more predictive of therapeutic effect, effective in clinical trials, innovative with decision-making data, accessible through investment and collaborative to respond to future challenges. With a team of over 140 specialists, our cutting-edge facilities are based at Alderley Park in Cheshire, UK. MDC is led by a highly skilled and engaged executive team and board who have an international reputation and extensive experience across all areas of Life Sciences.